¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Complement C1 Inhibitor Protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor
    ƯÀ̼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • alternative complement pathway
    ´ëüº¸Ã¼°æ·Î
  • classic complement pathway
    ÀüÇüÀûº¸Ã¼°æ·Î
  • complement
    º¸Ã¼, µµ¿òü
  • complement activation
    º¸Ã¼È°¼ºÈ­, µµ¿òüȰ¼ºÈ­
  • complement cascade
    º¸Ã¼¿¬¼â¹ÝÀÀ, µµ¿òü¿¬¼â¹ÝÀÀ
  • complement component
    º¸Ã¼¼ººÐ, µµ¿òü¼ººÐ
  • complement fixation
    º¸Ã¼°áÇÕ
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ
  • complement fixation test
    º¸Ã¼°áÇÕ°Ë»ç
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • protease inhibitor
    ´Ü¹éºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor
    ¼±ÅÃÀû¼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • alternative complement pathway
    º¸Ã¼´ëü°æ·Î, µµ¿òü´ëü°æ·Î
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
  • complement-fixing antibody
    µµ¿òü°áÇÕÇ×ü, º¸Ã¼°áÇÕÇ×ü
  • complement
    µµ¿òü, º¸Ã¼
  • complement-induced
    (¢¡complement-mediated) µµ¿òü¸Å°³-
  • complement-mediated
    µµ¿òü¸Å°³-
  • classic complement pathway
    º¸Ã¼ÀüÇüÀû°æ·Î, µµ¿òüÀüÇüÀû°æ·Î
  • complement cascade
    º¸Ã¼¿¬¼âÁõÆø¹ÝÀÀ
  • complement component
    µµ¿òü¼ººÐ
  • complement deficiency
    µµ¿òü°áÇÌ
  • complement fixation
    µµ¿òü°áÇÕ
  • complement profile
    µµ¿òÃ¼Ãø¸é»ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î »êÈ­È¿¼Ò ÀúÇØÁ¦.
  • MAO inhibitor(MAOI)
    ´Ü°¡¾Æ¹Î»êÈ­È¿¼Ò¾ïÁ¦Á¦
  • RIMA, see reversible inhibitor of MAO-A
    °¡¿ªÀû ´Ü°¡¾Æ¹Î-A »êÈ­È¿¼Ò¾ïÁ¦Á¦
  • acetylcholinesterase inhibitor
    ¾Æ¼¼Æ®Äݸ°¿¡½ºÅÍ·¹À̽º<¿¡½ºÅ×¶óÁ¦> ¾ïÁ¦Á¦.
  • angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅٽŠÀüȯȿ¼Ò ¾ïÁ¦¹°Áú<¾à>.
  • anti-inhibitor coagulation complex
    Ç×¾ïÁ¦Á¦ÀÀ°í°áÇÕü
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor
    ÀúÁöÀÚ, ¾ïÁ¦ÀÚ, ¾ïÁ¦ÀÎÀÚ
  • inhibitor
    ¾ïÁ¦ÀÚ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
  • inhibitor sensitive esterase
    ¾ïÁ¦¹°Áú¹ÝÀÀ¿¡½ºÅ×¶ó¾ÆÁ¦.
  • inter-alpha-trypsin inhibitor
    ÀÎÅÍ-¾ËÆÄ-Æ®¸³½Å ¾ïÁ¦Á¦
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
  • plasmin activation inhibitor
    Çö󽺹ÎȰ¼ºÈ­¾ïÁ¦Á¦(¡­üÀàõûùåäð¤ð¥)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cholinesterase inhibitor
    Äݸ°¿¡½ºÅ×¶óÁ¦ ¾ïÁ¦Á¦
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ ¾ïÁ¦Á¦<¾ïÁ¦ ¹°Áú
  • competitive inhibitor
    °æÀïÀû ¾ïÁ¦¹°.»ýÈ­°æÇÕÀû ÀúÇØ(ÌæùêîÜîÁúªð¥).
  • competitive inhibitor
    [»ýÈ­]°æÇÕÀúÇØÁ¦.
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦.
  • corrosion inhibitor
    ºÎ½Ä¹æÁöÁ¦(¡­ÛÁò­ð¥).
  • enzyme inhibitor
    È¿¼ÒÀúÇØÁ¦.
  • fertility inhibitor
    ¼öÁ¤¾ïÁ¦Á¦.
  • growth inhibitor
    ¼ºÀå<¹ßÀ°>¾ïÁ¦¹°Áú.
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor
    ¾ïÁ¦ÀÚ
  • inhibitor
    ÀúÁöÀÚ, ¾ïÁ¦ÀÚ, ¾ïÁ¦ÀÎÀÚ
  • inhibitor polymerization
    ÁßÇÕ¾ïÁ¦Á¦.
  • inhibitor sensitive esterase
    ¾ïÁ¦¹°Áú¹ÝÀÀ¿¡½ºÅ×¶ó¾ÆÁ¦.
  • insulinase inhibitor
    Àν¶¸®³ª¾ÆÁ¦ÀúÇØ¹°Áú, Àν¶¸°ºÐÇØÈ¿¼Ò¾ïÁ¦¹°Áú.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inhibitor constant
    ÀúÇØÁ¦»ó¼ö(îÁúªð¥ßÈâ¦)
  • irreversible inhibitor
    ºñ°¡¿ª ÀúÇØÁ¦(ުʦæ½îÁúªð¥)
  • Kunitz inhibitor
    Äï´ÏÃ÷ ÀúÇØÁ¦(îÁúªð­)
  • mixed-type inhibitor
    È¥ÇÕÇü ÀúÇØÁ¦(ûèùêúþîÁúªð¥)
  • noncompetitive inhibitor
    ºñ°áÇÕ ÀúÇØÁ¦(ު̿ùêîÁúªðº)
  • ovulation inhibitor
    ¹è¶õ ÀúÇØÁ¦(ÛÉÕ°îÁúªð¥)
  • respiratory inhibitor
    È£Èí ÀúÇØÁ¦(îÁúªð¥)
  • reversible inhibitor
    °¡¿ª ÀúÇØÁ¦(îÁúªð¥)
  • soybean trypsin inhibitor
    ´ëµÎ(ÓÞÔç) Æ®¸³½Å ÀúÇØÁ¦(îÁúªð¥)
  • transition state inhibitor
    õÀÌ»óÅ ÀúÇØÁ¦(ôÃì¹ßÒ÷¾îÁúªð¥)
  • Trojan horse inhibitor
    Æ®·ÎÀ̸ñ¸¶(ÙÊØ©) ÀúÇØÁ¦(îÁúªð¥)
  • uncompetitive inhibitor
    ¹«°æÇÕ(ÙíÌæùê) ÀúÇØÁ¦(îÁúªð¥)
  • accelerator protein
    ÃËÁø´Ü¹éÁú (õµòäÓ±ÛÜòõ)
  • acyl-carrier protein
    ¾Æ½Ç¿î¹Ý ´Ü¹éÁú (ê¡ÚæÓ±ÛÜòõ)
  • ada protein
    ada ´Ü¹éÁú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
C1 INH inhibitor of first component of complement
CLI complement lysis inhibitor; corpus luteum insufficiency
CRL cell repository line; Certified Record Librarian; complement receptor location; complement receptor ...
CAP camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab...
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NAIP Neuronal Apoptosis Inhibitor Protein
PCI Protein C inhibitor
PKI Protein kinase inhibitor
X-IAP X-linked inhibitor of apoptosis protein
ACP Alternative complement pathway
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cyclooxygenase inhibitor
    »çÀÌŬ·Î¿Á½ÃÁö³×ÀÌÁî ¾ïÁ¦Àç
  • dopa decarboxylase inhibitor
    µµÆÄ µ¥Ä«¸£º¹½Ç·¹À̽º ¾ïÁ¦ÀÚ
  • lipoxygenase inhibitor
    ¸®ÆÜ½ÃÁö³×À̽º ¾ïÁ¦Á¦
  • metabolic inhibitor
    ´ë»ç ÀúÇØÁ¦, ´ë»ç ¾ïÁ¦Á¦
  • polymerization inhibitor
    ÁßÇÕ ±ÝÁöÁ¦
    ÁßÇÕ ¹ÝÀÀÀ» ¹æÇØÇϱ⵵ Çϰí, ÁßÁöÇÒ ¼ö ÀÖ´Â ¹°Áú.
  • virus hemagglutination inhibitor
    ¹ÙÀÌ·¯½º ÀûÇ÷±¸ ÀÀÁý¹ÝÀÀ ¾ïÁ¦ ÀÎÀÚ
  • abnormal protein
    ºñÁ¤»ó ´Ü¹éÁú
  • activated protein C resistance
    Ȱ¼ºÈ­ C ´Ü¹é ³»¼º
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • androgen binding protein
    ³²¼º È£¸£¸ó °áÇÕ ´Ü¹é
  • bacterio protein
    ¼¼±Õ ´Ü¹éÁú
  • body protein
    ü´Ü¹é, ü´Ü¹éÁú
  • C-reactive protein
    C-¹ÝÀÀ ´Ü¹é, C-¹ÝÀÀ¼º ´Ü¹éÁú
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
  • chromatographic protein separation
    Å©·Î¸¶Åä±×·¡Çǹý ´Ü¹é ºÐ¸®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
mechanism-based inhibitor A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme.
Synonym: mechanism-based inhibitor.
(05 Mar 2000)
glucosidase inhibitor Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence.
(05 Mar 2000)
medication, ace-inhibitor Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart.
(12 Dec 1998)
residual inhibitor A sound-generating device, worn in the ear, which inhibits or suppresses the sounds of tinnitus by masking, with a residual inhibitory effect when the device is turned off.
(05 Mar 2000)
respiratory inhibitor A compound that inhibits the respiratory chain.
Synonym: respiratory poison.
(05 Mar 2000)
cholinesterase inhibitor <pharmacology> These are substances which which act to inhibit acetylcholinesterase, the enzyme which breaks down acetylcholine and thus enhance and subsequently prevent transmission of nerve impulses from one nerve cell to another or to a muscle.
Examples include pyridostigmine, ambenonium and neostigmine.
(15 Jan 1998)
monoamine oxidase inhibitor <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression.
Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions.
Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine.
Acronym: MAOI
(26 Mar 1998)
plasminogen activator inhibitor 1 <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
plasminogen activator inhibitor 2 <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
cyclooxygenase inhibitor <pharmacology> Compounds or agents that combine with cyclooxygenase (prostaglandin-endoperoxide synthase) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.
(08 Mar 2000)
protease inhibitor A drug that binds to and blocks HIV protease from working, thus preventing the production of new infectious viral articles.
(09 Oct 1997)
proteinase inhibitor inducing factor See: PIIF.
(18 Nov 1997)
proton pump inhibitor <pharmacology> A group of anti-ulcer medications which work by binding to H+/K+ ATPase, an enzyme which is found on the secretory surface of parietal cells. It thereby inhibits the final transport of hydrogen ions (via exchange with potasium) into the gastric lumen.
Examples of proton pump inhibitors include omeprazole and lansoprazole.
(27 Sep 1997)
HMG CoA reductase inhibitor Drugs, such as lovastatin and pravastatin, which interfere with the biosynthesis of cholesterol; used to treat hyperlipidemia.
(05 Mar 2000)
selective serotonin reuptake inhibitor <pharmacology> This is a class of drug that are used as antidepressants.
Functionally, they increase the levels of serotonin in the body. These drugs can be dangerous if they are mixed with other drugs such as other antidepressants, illicit drugs (LSD, cocaine, methamphetamine), some antihistamines (Seldane, Histmanal), some antibiotics, and calcium channel blockers.
Side effects include lethargy, confusion, flushing, sweating and muscle spasms. Overdose can cause damage to red blood cells, breathing problems and kidney damage.
Examples include: Prozac, Zoloft and Paxil.
Acronym: SSRI
(12 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á